Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;65(7):753-759.
doi: 10.1111/myc.13470. Epub 2022 May 31.

Emergence of Candida auris in intensive care units in Algeria

Hanane Zerrouki  1   2   3 , Ahmad Ibrahim  1   2 , Sid-Ahmed Rebiahi  3 , Yamina Elhabiri  3 , Djamel-Eddine Benhaddouche  4 , Theun de Groot  5   6 , Jacques F Meis  5   6 , Jean-Marc Rolain  1   2 , Fadi Bittar  1   2
Affiliations

Emergence of Candida auris in intensive care units in Algeria

Hanane Zerrouki et al. Mycoses. 2022 Jul.

Abstract

Background: Currently, Candida auris is among the most serious emerging pathogens that can be associated with nosocomial infections and outbreaks in intensive care units. Clinicians must be able to identify and manage it quickly.

Objective: Here, we report for the first time in Algeria seven cases of C. auris infection or colonisation.

Methods and results: The strains were isolated from clinical sites including bronchial aspirates (n = 4), wound swabs (n = 1), urine sample (n = 1) and peritoneal fluid (n = 1), in patients admitted to the intensive care unit. Candida auris was identified both by MALDI-TOF and by sequencing the ITS region and the D1/D2 domain. Antifungal susceptibility testing was performed using the E-test method. Non-wildtype susceptibility was observed for five strains against fluconazole, itraconazole, voriconazole and caspofungin. Genotyping showed the presence of four clades (I-IV) in one hospital.

Conclusions: Appropriate antifungal treatments with rapid and accurate microbial identification are the cornerstone for the management and control of C. auris infections.

Keywords: Candida auris; Algeria; ICU; clades (I-IV); emergence.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
UPGMA dendrogram of STR of seven Candida auris isolates from this study and 67 strains originating from various countries and clades. The Algerian isolates clustered in clade I with isolates from India, in clade II with isolates from East Asia, in clade III with isolates from South Africa and in clade IV with isolates from South America
See this image and copyright information in PMC

References

    1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:41‐44. - PubMed
    1. Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020;16(10):e1008921. - PMC - PubMed
    1. Desnos‐Ollivier M, Fekkar A, Bretagne S. Earliest case of Candida auris infection imported in 2007 in Europe from India prior to the 2009 description in Japan. J Med Mycol. 2021;31(3):101139. - PubMed
    1. de Jong AW, Hagen F. Attack, defend and persist: how the fungal pathogen Candida auris was able to emerge globally in healthcare environments. Mycopathologia. 2019;184(3):353‐365. - PubMed
    1. Osei Sekyere J. Candida auris: A systematic review and meta‐analysis of current updates on an emerging multidrug‐resistant pathogen. Microbiology. 2018;7(4):e00578. - PMC - PubMed

Substances